Natalia Buza

Summary

Affiliation: Yale University
Country: USA

Publications

  1. doi request reprint Partial hydatidiform mole: histologic parameters in correlation with DNA genotyping
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Int J Gynecol Pathol 32:307-15. 2013
  2. doi request reprint Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, 310 Cedar St, LH 108, PO 208023, New Haven, CT 06520, USA
    Int J Gynecol Pathol 28:514-21. 2009
  3. doi request reprint Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder
    Natalia Buza
    Yale University, School of Medicine, New Haven, CT 06520 8023, USA
    Int J Surg Pathol 18:94-102. 2010
  4. doi request reprint Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
    Virchows Arch 457:337-45. 2010
  5. pmc Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
    Dana M Roque
    Division of Gynecologic Oncology, Yale University School of Medicine, 333 Cedar Street FMB 328, Box 208063, New Haven, CT, 06520, USA
    Clin Exp Metastasis 31:101-10. 2014
  6. pmc HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas
    Federica Guzzo
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Int J Gynecol Pathol 31:211-21. 2012
  7. pmc Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
    Joyce Varughese
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Am J Obstet Gynecol 205:567.e1-7. 2011
  8. pmc Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor
    Emiliano Cocco
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Clin Exp Metastasis 28:689-700. 2011
  9. doi request reprint Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
    Dana M Roque
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT
    Am J Obstet Gynecol 209:62.e1-9. 2013
  10. pmc Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones
    Dana M Roque
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer 119:2582-92. 2013

Collaborators

Detail Information

Publications25

  1. doi request reprint Partial hydatidiform mole: histologic parameters in correlation with DNA genotyping
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Int J Gynecol Pathol 32:307-15. 2013
    ..The presence of any one of the following histologic findings should prompt DNA genotyping workup to rule out PHM: round or oval pseudoincludions, cistern formation, 2 populations of villi, and a villous size of ≥2.5 mm...
  2. doi request reprint Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, 310 Cedar St, LH 108, PO 208023, New Haven, CT 06520, USA
    Int J Gynecol Pathol 28:514-21. 2009
    ..Compared with p53, p16 immunoreactivity is significantly more intense and diffuse in both components. Our findings indicate that alterations in the p16-Rb pathway play an important role in the pathogenesis of uterine MMMTs...
  3. doi request reprint Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder
    Natalia Buza
    Yale University, School of Medicine, New Haven, CT 06520 8023, USA
    Int J Surg Pathol 18:94-102. 2010
    ..6% (Chr) and 71.4% (CD56) in SmCCs. P16 positivity in the absence of p63 and CK20 is highly characteristic of SmCC, while p63 and CK20 positivity with or without p16 expression is typical of HG-UCC...
  4. doi request reprint Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
    Virchows Arch 457:337-45. 2010
    ..MEC is a potentially aggressive malignant neoplasm sharing many features with metaplastic carcinomas. Morphologically, it is often difficult to distinguish it from benign spindle cell proliferations...
  5. pmc Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
    Dana M Roque
    Division of Gynecologic Oncology, Yale University School of Medicine, 333 Cedar Street FMB 328, Box 208063, New Haven, CT, 06520, USA
    Clin Exp Metastasis 31:101-10. 2014
    ..Decreases in stromal expression may represent normalization of the tumor microenvironment following therapy. Epothilones warrant study for patients who have received neoadjuvant carboplatin and paclitaxel...
  6. pmc HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas
    Federica Guzzo
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Int J Gynecol Pathol 31:211-21. 2012
    ..Our results suggest that HER2/neu may represent a novel target for the immunotherapy of a subset of human carcinosarcomas refractory to salvage chemotherapy...
  7. pmc Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
    Joyce Varughese
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Am J Obstet Gynecol 205:567.e1-7. 2011
    ..We evaluated the expression of human trophoblast cell-surface marker (Trop-2) and the potential of hRS7, a humanized monoclonal anti-Trop-2 antibody, against treatment-refractory cervical cancer...
  8. pmc Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor
    Emiliano Cocco
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Clin Exp Metastasis 28:689-700. 2011
    ....
  9. doi request reprint Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
    Dana M Roque
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT
    Am J Obstet Gynecol 209:62.e1-9. 2013
    ..In this study, we clarify the relationship between class III β-tubulin and p-glycoprotein expression in clear cell carcinoma of the ovary, clinical outcome, and in vitro responsiveness to patupilone and paclitaxel...
  10. pmc Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones
    Dana M Roque
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer 119:2582-92. 2013
    ....
  11. pmc Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
    Rhoda Raji
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    J Exp Clin Cancer Res 30:106. 2011
    ....
  12. pmc Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor
    Emiliano Cocco
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06519, USA
    BMC Cancer 11:263. 2011
    ....
  13. doi request reprint The significance of perineural invasion in early-stage cervical cancer
    Karim S Elsahwi
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, CT, USA
    Gynecol Oncol 123:561-4. 2011
    ..Cervical cancer spreads directly and through lymphatic and vascular channels. Perineural invasion is an alternative method of spread. Several risk factors portend poor prognosis and inform management decisions regarding adjuvant therapy...
  14. pmc Serum amyloid A: a novel biomarker for endometrial cancer
    Emiliano Cocco
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut 06520 8063, USA
    Cancer 116:843-51. 2010
    ..The authors investigated the expression of serum amyloid A (SAA) in endometrial endometrioid carcinoma and evaluated its potential as a serum biomarker...
  15. doi request reprint Cancerous 'floater': a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability
    Veerle Bossuyt
    Department of Pathology, Yale University School of Medicine, New Haven, CT06520 8023, USA
    Mod Pathol 26:1264-9. 2013
    ..Awareness of this phenomenon is crucial for a molecular pathologist to avoid interpretation errors of tissue identity testing in a cancer diagnostic workup...
  16. pmc Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
    Siming Zhao
    Department of Genetics, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 110:2916-21. 2013
    ..These findings identify frequent mutation of DNA damage, chromatin remodeling, cell cycle, and cell proliferation pathways in USC and suggest potential targets for treatment of this lethal variant of endometrial cancer...
  17. ncbi request reprint Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability
    Melissa Much
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Hum Pathol 45:549-55. 2014
    ..Careful examination of the STR allelic pattern, high index of suspicion, and follow-up MSI testing are crucial to avoid erroneous conclusions and subsequent clinical and legal consequences. ..
  18. ncbi request reprint HER-2/NEU overexpression in vulvar Paget disease: the Yale experience
    Christine E Richter
    Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Pathol 63:544-7. 2010
    ..To determine the level of HER-2/neu overexpression in vulvar Paget disease (PD) in order to assess the possibility of using HER-2/neu as a target for the treatment of Paget disease...
  19. ncbi request reprint HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
    Natalia Buza
    From the Departments of Pathology Dr Buza and Obstetrics, Gynecology, and Reproductive Sciences Drs Roque and Santin, Yale University School of Medicine, New Haven, Connecticut and the Gynecologic Oncology Program, Yale Cancer Center, New Haven, Connecticut Dr Santin
    Arch Pathol Lab Med 138:343-50. 2014
    ....
  20. doi request reprint Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    Mod Pathol 26:1605-12. 2013
    ..Assessment of HER2 immunohistochemistry on multiple tumor sections or sections with large tumor areas is recommended, due to the significant heterogeneity of HER2 protein expression...
  21. pmc Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201)
    Karim El-Sahwi
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut 06520 8063, USA
    Mol Cancer Ther 9:57-66. 2010
    ..MT201 might represent a novel therapeutic strategy in patients harboring advanced/recurrent or metastatic USPC refractory to standard treatment modalities...
  22. ncbi request reprint Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium
    Ahmed Alomari
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    Mod Pathol 27:675-80. 2014
    ..With a high PPV, KRAS mutation analysis may offer an additional discriminatory power to refine risk stratification algorithm for patients with endometrial mucinous lesions. ..
  23. doi request reprint Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, New Haven, CT, 06520 8023
    Genes Chromosomes Cancer 52:1178-86. 2013
    ..Direct comparison with the HER2 immunostaining pattern may be helpful in detecting HER2 amplified areas in a heterogeneous tumor...
  24. ncbi request reprint Immunohistochemistry and other ancillary techniques in the diagnosis of gestational trophoblastic diseases
    Natalia Buza
    Department of Pathology, Yale University School of Medicine, 310 Cedar St, New Haven, Connecticut 06520
    Semin Diagn Pathol 31:223-32. 2014
    ..Beyond hydatidiform mole, recognition of gestational trophoblastic tumors requires a high index of suspicion and application of immunohistochemical markers of trophoblast is helpful to accurately diagnose these rare tumors. ..
  25. doi request reprint Genotyping diagnosis of nongestational choriocarcinoma involving fallopian tube and broad ligament: a case study
    Natalia Buza
    Departments of Pathology N B, P H Obstetrics, Gynecology and Reproductive Sciences T R, P H, Yale University School of Medicine, New Haven, Connecticut
    Int J Gynecol Pathol 33:58-63. 2014
    ..The patient received 1 additional cycle of multiagent chemotherapy. She was alive without evidence of recurrence 26 months after the initial diagnosis. ..